Calcium Alpha-Ketoglutarate (Ca-AKG) is a key metabolite in the Krebs cycle, crucial for cellular energy production. It is being studied for its potential to inhibit mTOR and act as a cofactor for epigenetic demethylation enzymes. The liposomal formulation encapsulates Ca-AKG in a lipid layer to protect it from stomach acid and enhance absorption, aiming for higher bioavailability and systemic effect compared to standard forms.
Verdict
A promising but experimental agent based on strong mouse data.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Low
EVIDENCE GRADE
C
MONTHLY COST
$60 - $120
Protocol
- Take 300-500 mg of liposomal Ca-AKG once daily, typically in the morning on an empty stomach.
Flags
- Liposomal delivery significantly increases bioavailability; do not use standard Ca-AKG dosages.
- Human evidence is currently limited to a non-randomized, industry-sponsored observational study.
- Individuals with kidney issues or hypercalcemia should consult a physician due to the calcium content.
- Long-term effects of sustained supplementation in humans are not well-established.